FluidAI Medical announces an acquisition deal with Emmetros Limited

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

FluidAI Medical, a medical technology company that develops novel hardware, software, and artificial intelligence (AI) solutions, recently announced an acquisition deal with SparxConnect developer Emmetros Limited, a leading company in the patient engagement space. The acquisition enhances Stream Inara™, an AI-powered patient education and engagement platform within FluidAI's product portfolio that extends care beyond the hospital.

FluidAI Medical is an OBIO® member, an alumnus of our BDSP™, CAAP®, EAHN™, H2BB™, HealthMINT™, Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence and WiHI programs, and presented at the OBIO® Investment Summit.

Read more
Arsheen Kaur
Previous

Kixcare partners with Manulife to provide 24x7 virtual care for children across Canada
Next

Capital BioVentures launches first cohort for the ASCENT program: Fit for funding, empowering breakthrough biotech